Base de dados : MEDLINE
Pesquisa : D02.033.100.350 [Categoria DeCS]
Referências encontradas : 42 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 5 ir para página              

  1 / 42 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:26240886
[Ti] Título:Drugs for hypotension: disproportionate harms with etilefrine and heptaminol. .
[So] Source:Prescrire Int;24(162):184, 2015 Jul.
[Is] ISSN:1167-7422
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:The French Health Products Agency concluded that etilefrine and heptaminol have an unfavourable harm-benefit balance, and also placed restrictions on the use of midodrine.
[Mh] Termos MeSH primário: Etilefrina/efeitos adversos
Heptaminol/efeitos adversos
Hipotensão/tratamento farmacológico
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
3DQS188SY5 (Heptaminol); ZB6F8MY53V (Etilefrine)
[Em] Mês de entrada:1508
[Cu] Atualização por classe:150804
[Lr] Data última revisão:
150804
[Sb] Subgrupo de revista:T
[Da] Data de entrada para processamento:150805
[St] Status:MEDLINE


  2 / 42 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:20720484
[Au] Autor:Bahloul M; Chaari A; Ben Mbarek MN; Kallel H; Bouaziz M
[Ad] Endereço:Department of Intensive Care, Habib Bourguiba University Hospital, Sfax, Tunisia.
[Ti] Título:Use of heptaminol hydrochloride for catecholamine weaning in septic shock.
[So] Source:Am J Ther;19(1):e8-17, 2012 Jan.
[Is] ISSN:1536-3686
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We analyze in the current study the impact of heptaminol hydrochloride (Heptamyl) administration in patients with septic shock requiring adrenergic support on the duration of vasopressor infusion and on catecholamine delay weaning. In this prospective study were included 49 nonconsecutive patients with septic shock requiring vasopressor infusion and with stable hemodynamic parameters during more than 24 hours. All these patients were included in a random way to receive or not heptaminol hydrochloride. The primary end point was the effect of heptaminol hydrochloride administration on duration of weaning, defined as cessation of vasopressor support. There were 32 males (65%) and 17 females (35%). The mean age (± standard deviation) was 53.9 ± 22.2 years. Norepinephrine was the most commonly used vasopressor agent (73.4%). The comparison between two groups (with and without heptaminol hydrochloride) showed that two groups had the same epidemiologic, clinical, and biologic findings on intensive care unit admission. In our study, we found that the introduction of Heptamyl was associated with a quick decrease of dose of dopamine and norepinephrine in comparison with the Heptamyl-free group. By comparing the two groups, we found that the delay of catecholamine weaning was significantly faster for the dopamine (P = 0.008) and noradrenalin (P = 0.001) in the Heptamyl group. Finally, the intensive care unit mortality rate and the hospital mortality rate were significantly lower in the Heptamyl group. Our study shows a reduction in norepinephrine and dopamine weaning duration in septic patients enrolled in the heptaminol hydrochloride group.
[Mh] Termos MeSH primário: Dopamina/administração & dosagem
Heptaminol/farmacologia
Norepinefrina/administração & dosagem
Choque Séptico/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Dopamina/uso terapêutico
Feminino
Mortalidade Hospitalar
Seres Humanos
Unidades de Terapia Intensiva/estatística & dados numéricos
Masculino
Meia-Idade
Norepinefrina/uso terapêutico
Estudos Prospectivos
Choque Séptico/mortalidade
Choque Séptico/fisiopatologia
Fatores de Tempo
Vasoconstritores/administração & dosagem
Vasoconstritores/uso terapêutico
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Vasoconstrictor Agents); 3DQS188SY5 (Heptaminol); VTD58H1Z2X (Dopamine); X4W3ENH1CV (Norepinephrine)
[Em] Mês de entrada:1205
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:100820
[St] Status:MEDLINE
[do] DOI:10.1097/MJT.0b013e3181e9b630


  3 / 42 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:19450409
[Au] Autor:Gharibi L; Zouhair K; Ramdani B; Benchikhi H
[Ti] Título:Hair lightening in an hemodialysis patient treated by heptaminol (heptamyl).
[So] Source:Dermatol Online J;15(4):16, 2009 Apr 15.
[Is] ISSN:1087-2108
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Hair lightening occurred in a patient treated with heptaminol (heptamyl). This patient had chronic renal failure and had been undergoing hemodialysis since 2003. The hair hypopigmentation reversed after stopping the drug. The mechanism of the hair color modification is not understood.
[Mh] Termos MeSH primário: Cor de Cabelo
Heptaminol/farmacologia
Hipopigmentação/induzido quimicamente
Hipotensão/tratamento farmacológico
Diálise Renal
[Mh] Termos MeSH secundário: Adulto
Seres Humanos
Falência Renal Crônica/complicações
Falência Renal Crônica/terapia
Masculino
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
3DQS188SY5 (Heptaminol)
[Em] Mês de entrada:0908
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:090520
[St] Status:MEDLINE


  4 / 42 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:16872566
[Au] Autor:Tseng YL; Liu CH; Kuo FH; Shieh MH
[Ad] Endereço:Institute of Pharmacology and Toxicology and Doping Control Center, Tzu Chi University, Hualien, Taiwan. hing@mail.tcu.edu.tw
[Ti] Título:Solid-phase column chromatographic and gas chromatographic-mass spectrometric determination of heptaminol in human urine and related pharmacokinetic profiles.
[So] Source:J Anal Toxicol;30(6):365-9, 2006 Jul-Aug.
[Is] ISSN:0146-4760
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Heptaminol is an antihypotensive drug and is one of the stimulants banned in sport competitions. When heptaminol was fortified to a drug-free urine sample and subjected to solid-phase extraction, trifluroacetic anhydride derivatization, and gas chromatography-mass spectrometry analysis, the results indicated three chromatographic peaks, with one major peak [peak 1 (P1) as heptaminol-2TFA], appearing at retention time 7.17 min, and two minor peaks [peak 2 (P2) and peak 3 (P3) as heptaminol-TFA], appearing at RT 5.87 and 5.81 min, respectively. The characteristic ions of peak mass spectra were m/z 322, 224, and 140 for P1, m/z 223 (molecular ion), 208, 140, and 110 for P2, and m/z 208, 140, and 110 for P3. The urine samples collected from healthy male volunteers who orally ingested a single dose (100 mg) of heptaminol were similar to the analytical results shown in the heptaminol-spiked control urine samples. This result suggested that the unchanged heptaminol was the sole form found in urine. The unchanged parent compound was completely eliminated in urine within 24 h and an average of approximately 97% of the dose was excreted through the renal pathway.
[Mh] Termos MeSH primário: Cardiotônicos/urina
Doping nos Esportes
Cromatografia Gasosa-Espectrometria de Massas/métodos
Heptaminol/urina
Detecção do Abuso de Substâncias/métodos
[Mh] Termos MeSH secundário: Anidridos Acéticos
Administração Oral
Adulto
Cardiotônicos/administração & dosagem
Cardiotônicos/farmacocinética
Fluoracetatos
Heptaminol/administração & dosagem
Heptaminol/farmacocinética
Seres Humanos
Masculino
Meia-Idade
Reprodutibilidade dos Testes
Ácido Trifluoracético/química
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Acetic Anhydrides); 0 (Cardiotonic Agents); 0 (Fluoroacetates); 3DQS188SY5 (Heptaminol); 5ENA87IZHT (trifluoroacetic anhydride); E5R8Z4G708 (Trifluoroacetic Acid)
[Em] Mês de entrada:0708
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:060729
[St] Status:MEDLINE


  5 / 42 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:16242387
[Au] Autor:Lyris E; Tsiakatouras G; Angelis Y; Koupparis M; Spyridaki MH; Georgakopoulos C
[Ad] Endereço:Doping Control Laboratory of Athens, Olympic Athletic Center of Athens, Kifissias 37, 15123 Maroussi, Greece.
[Ti] Título:Metabolism of isometheptene in human urine and analysis by gas chromatography-mass spectrometry in doping control.
[So] Source:J Chromatogr B Analyt Technol Biomed Life Sci;827(2):199-204, 2005 Dec 05.
[Is] ISSN:1570-0232
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:A study of the metabolism of isometheptene, an antispasmodic drug, in man and comparison with heptaminol metabolism, is presented in this paper. Isometheptene and two metabolites were detected in human urine after oral administration of a tablet containing isometheptene mucate. The urine level of the parent drug, which is excreted during the first 24 h, was determined using gas chromatography-mass spectrometry, after alkaline extraction with organic solvent. A minor metabolite of isometheptene was converted to heptaminol in vitro under the acidic hydrolysis conditions used for the screening procedure of stimulants and narcotics in doping control analysis.
[Mh] Termos MeSH primário: Doping nos Esportes/prevenção & controle
Cromatografia Gasosa-Espectrometria de Massas/métodos
Metilaminas/urina
[Mh] Termos MeSH secundário: Administração Oral
Heptaminol/metabolismo
Seres Humanos
Metilaminas/administração & dosagem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Methylamines); 3DQS188SY5 (Heptaminol); Y7L24THH6T (isometheptene)
[Em] Mês de entrada:0602
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:051026
[St] Status:MEDLINE


  6 / 42 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:15991040
[Au] Autor:Pathak A; Raoul V; Montastruc JL; Senard JM
[Ad] Endereço:Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Hôpitaux de Toulouse, 37 allées Jules Guesde, 31073, Toulouse cedex 7, France.
[Ti] Título:Adverse drug reactions related to drugs used in orthostatic hypotension: a prospective and systematic pharmacovigilance study in France.
[So] Source:Eur J Clin Pharmacol;61(5-6):471-4, 2005 Jul.
[Is] ISSN:0031-6970
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The aim of the present study was to investigate and characterise adverse drug reactions (ADRs) to drugs used in France for orthostatic hypotension (OH). METHODS: In this prospective and systematic study, 121 consecutive out-patients suffering from primary (Parkinson's disease, pure autonomic failure, multiple system atrophy, Lewy bodies disease) or secondary (diabetic and non-diabetic peripheral neuropathies) autonomic failure with symptomatic OH requiring pharmacological treatment with at least one drug marketed in France for OH were included together with six patients with refractory neurocardiogenic syncope. RESULTS: Of the patients, 85 received a monotherapy-mainly with midodrine (49.4%)-and 42 received various combinations, the association of midodrine and fludrocortisone being the most frequent (66.6%). Of all the 127 patients, 88 suffered from a total of 141 ADRs (1.60 per patient) with no statistical difference in ADR frequency between monotherapy and drug combinations (P>0.05). Among ADRs, 24 (17.0%) were considered as "serious" and 16 (11.3%) were considered as "unexpected", most of them observed with heptaminol. CONCLUSIONS: This study shows a high frequency of ADRs (especially serious and unexpected ADRs) with antihypotensive drugs. It strongly suggests the need for a better evaluation of the safety profile of antihypotensive drugs and improvement in summary of product characteristics.
[Mh] Termos MeSH primário: Fludrocortisona/efeitos adversos
Heptaminol/efeitos adversos
Hipotensão Ortostática/tratamento farmacológico
Midodrina/efeitos adversos
[Mh] Termos MeSH secundário: Sistemas de Notificação de Reações Adversas a Medicamentos
Bases de Dados Factuais
Serviços de Informação sobre Medicamentos
Monitoramento de Medicamentos
Feminino
Fludrocortisona/uso terapêutico
França
Heptaminol/uso terapêutico
Seres Humanos
Masculino
Midodrina/uso terapêutico
Estudos Prospectivos
Medição de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
3DQS188SY5 (Heptaminol); 6YE7PBM15H (Midodrine); U0476M545B (Fludrocortisone)
[Em] Mês de entrada:0609
[Cu] Atualização por classe:171121
[Lr] Data última revisão:
171121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:050702
[St] Status:MEDLINE


  7 / 42 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:15061296
[Au] Autor:Sumboonnanonda K; Lertsithichai P
[Ad] Endereço:Department of Surgery, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.
[Ti] Título:Clinical study of the Ginko biloba--Troxerutin-Heptaminol Hce in the treatment of acute hemorrhoidal attacks.
[So] Source:J Med Assoc Thai;87(2):137-42, 2004 Feb.
[Is] ISSN:0125-2208
[Cp] País de publicação:Thailand
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The aim of this study was to assess the clinical efficacy, compliance and safety of Ginko biloba--Troxerutin-Heptaminol Hce in the treatment of patients with acute hemorrhoidal attacks in Thailand. MATERIAL AND METHOD: In a prospective clinical study on hospital outpatients, the authors studied the effect of Ginko biloba--Troxerutin-Heptaminol Hce for a week in adults (18-70 years old) with acute hemorrhoidal attacks. RESULT: Twenty-two patients, with a mean age of 41.7 years were included in the study. The male to female ratio was 1 : 1.2. Most patients (77%) had grade 1 and 2 hemorrhoids with an average duration of attacks of 3 days. On intention to treat analysis, bleeding, pain, tenesmus and discharge were significantly improved. Treatment was well accepted and safe. CONCLUSION: In the short-term, Ginko biloba--Troxerutin-Heptaminol Hce is effective, acceptable and safe in the treatment of patients with acute hemorrhoidal attacks.
[Mh] Termos MeSH primário: Ginkgo biloba
Hemorroidas/tratamento farmacológico
Heptaminol/uso terapêutico
Hidroxietilrutosídeo/uso terapêutico
Fitoterapia/métodos
[Mh] Termos MeSH secundário: Doença Aguda
Adolescente
Adulto
Idoso
Quimioterapia Combinada
Feminino
Seguimentos
Hemorroidas/diagnóstico
Seres Humanos
Hidroxietilrutosídeo/análogos & derivados
Masculino
Meia-Idade
Medição da Dor
Estudos Prospectivos
Medição de Risco
Índice de Gravidade de Doença
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL; COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hydroxyethylrutoside); 3DQS188SY5 (Heptaminol); 7Y4N11PXO8 (troxerutin)
[Em] Mês de entrada:0404
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:040406
[St] Status:MEDLINE


  8 / 42 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11468252
[Au] Autor:Edno-Mcheik L; Gaulier JM; Combourieu I; Lacassie E; Hadzic A
[Ti] Título:Heptaminol interferes in the AxSYM FPIA amphetamine/methamphetamine II assay.
[So] Source:Clin Chem;47(8):1499-500, 2001 Aug.
[Is] ISSN:0009-9147
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Anfetamina/urina
Cardiotônicos/urina
Heptaminol/urina
Metanfetamina/urina
Vasodilatadores/urina
[Mh] Termos MeSH secundário: Cromatografia Líquida de Alta Pressão
Reações Falso-Positivas
Cromatografia Gasosa-Espectrometria de Massas
Seres Humanos
[Pt] Tipo de publicação:LETTER
[Nm] Nome de substância:
0 (Cardiotonic Agents); 0 (Vasodilator Agents); 3DQS188SY5 (Heptaminol); 44RAL3456C (Methamphetamine); CK833KGX7E (Amphetamine)
[Em] Mês de entrada:0108
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:010727
[St] Status:MEDLINE


  9 / 42 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:10434151
[Au] Autor:Regina W; Vandel P; Vandel S; Sechter D; Bizouard P
[Ad] Endereço:Service de Psychiatrie et Psychologie Médicale, CHU Saint-Jacques, Besançon.
[Ti] Título:[Clinical tolerance of a new antidepressant -- milnacipran].
[Ti] Título:Tolérance clinique d'un nouvel antidépresseur, le milnacipran..
[So] Source:Encephale;25(3):252-8, 1999 May-Jun.
[Is] ISSN:0013-7006
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:Milnacipran is a new antidepressant which has been developed for its selective inhibition of both serotonin and noradrenaline reuptake with a good safety and tolerability profile. The efficacy and tolerance profile of this antidepressant have been compared with those of tricyclic and selective serotonin reuptake inhibitor antidepressants (SSRIs) in open-label and placebo-controlled trials. But no data in clinical practice are available. The authors studied the tolerability of milnacipran (100 to 200 mg/d) in 28 depressed inpatients receiving usual comedications during a mean period of 33 days (3 to 107 days). The incidence of adverse events was determined with the help of the Pharmacovigilance Center of the Centre Hospitalo-Universitaire (Besançon, France). Among the 28 patients, milnacipran was well tolerated by 18 of them. Side-effects were noted in 10 patients, but they led to withdrawal of the antidepressant in only 2 cases, where dyspnea, palpitations, pollakiuria in a case and headache, nausea, dysuria in the other case occurred. The most frequent adverse event observed was hypotension (n = 6), but in each case it occurred just after the addition of sedative phenothiazines (n = 5) or of a comedication with phenothiazines and valpromide (n = 1). So this side-effect could not be attributed to milnacipran alone. Treatments with heptaminol or theodrenaline and cafedrine were useful. An increase of the cardiac frequency seemed to occur with milnacipran (p < 0.06). It was observed in the 5 inpatients for whom this cardiovascular parameter was recorded before and during the milnacipran treatment. In 5 other patients, the cardiac frequency seemed to decrease when milnacipran was stopped for lack of good efficacy or adverse events. Gastrointestinal disturbances were scarce isolated (nausea n = 1), but necessitated a treatment with metopimazine. The milnacipran prescription (100 mg/d) after an other antidepressant treatment had been done without a withdrawal period and without problem, even when the previous antidepressant was a SSRIs with a long half-life and CYP450 inhibitory properties. The authors concluded to the good tolerability of milnacipran in usual clinical practice.
[Mh] Termos MeSH primário: Ciclopropanos/efeitos adversos
Transtorno Depressivo Maior/tratamento farmacológico
Inibidores da Captação de Serotonina/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Idoso
Doenças Cardiovasculares/induzido quimicamente
Doenças Cardiovasculares/prevenção & controle
Transtorno Depressivo Maior/reabilitação
Relação Dose-Resposta a Droga
Quimioterapia Combinada
Feminino
Heptaminol/uso terapêutico
Hospitalização
Seres Humanos
Hipotensão/induzido quimicamente
Masculino
Meia-Idade
Fenilpropanolamina/análogos & derivados
Fenilpropanolamina/uso terapêutico
Teofilina/análogos & derivados
Teofilina/uso terapêutico
Fatores de Tempo
Resultado do Tratamento
Vasodilatadores/uso terapêutico
[Pt] Tipo de publicação:CLINICAL TRIAL; COMPARATIVE STUDY; ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cyclopropanes); 0 (Serotonin Uptake Inhibitors); 0 (Vasodilator Agents); 0UYY5V4U2Q (cafedrine); 33RU150WUN (Phenylpropanolamine); 3DQS188SY5 (Heptaminol); C137DTR5RG (Theophylline); G56VK1HF36 (milnacipran)
[Em] Mês de entrada:9912
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:990806
[St] Status:MEDLINE


  10 / 42 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:7758651
[Au] Autor:Vendittelli F; Alain J; Nouaille Y; Brosset A; Tabaste JL
[Ad] Endereço:C.H.U. de Limoges. Service de Gynécologie-Obstétrique II, Limoges, France.
[Ti] Título:A case of lipomeningocele reported with fluoxetine (and alprazolam, vitamins B1 and B6, heptaminol) prescribed during pregnancy.
[So] Source:Eur J Obstet Gynecol Reprod Biol;58(1):85-6, 1995 Jan.
[Is] ISSN:0301-2115
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Mh] Termos MeSH primário: Fluoxetina/efeitos adversos
Lipoma/induzido quimicamente
Meningocele/induzido quimicamente
Disrafismo Espinal/induzido quimicamente
[Mh] Termos MeSH secundário: Adulto
Alprazolam/efeitos adversos
Alprazolam/uso terapêutico
Depressão/tratamento farmacológico
Quimioterapia Combinada
Feminino
Fluoxetina/uso terapêutico
Heptaminol/efeitos adversos
Heptaminol/uso terapêutico
Seres Humanos
Recém-Nascido
Lipoma/complicações
Lipoma/diagnóstico
Meningocele/complicações
Meningocele/diagnóstico
Gravidez
Complicações na Gravidez/tratamento farmacológico
Piridoxina/efeitos adversos
Piridoxina/uso terapêutico
Disrafismo Espinal/complicações
Disrafismo Espinal/diagnóstico
Tiamina/efeitos adversos
Tiamina/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
01K63SUP8D (Fluoxetine); 3DQS188SY5 (Heptaminol); KV2JZ1BI6Z (Pyridoxine); X66NSO3N35 (Thiamine); YU55MQ3IZY (Alprazolam)
[Em] Mês de entrada:9506
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:950101
[St] Status:MEDLINE



página 1 de 5 ir para página              
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde